Wedbush Downgrades Fate Therapeutics (FATE) to Neutral
Get Alerts FATE Hot Sheet
Price: $7.34 --0%
Rating Summary:
9 Buy, 15 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Rating Summary:
9 Buy, 15 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE
Wedbush analyst David Nierengarten downgraded Fate Therapeutics (NASDAQ: FATE) from Outperform to Neutral with a price target of $88.00.
For an analyst ratings summary and ratings history on Fate Therapeutics click here. For more ratings news on Fate Therapeutics click here.
Shares of Fate Therapeutics closed at $86.27 yesterday.
You May Also Be Interested In
- Monness, Crespi, Hardt Downgrades Palantir Technologies Inc. (PLTR) to Sell on 'egregiously rich valuation... darkest days of this economic downturn are ahead of us'
- BofA Securities Downgrades Molina Healthcare (MOH) to Underperform
- Sidoti Downgrades Construction Partners Inc (ROAD) to Neutral
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!